Project Grant R43TR005259
Award Date
9/5/24
Completion Date
8/31/25
Dollars Obligated
$317K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15217, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training Program provides $308,925 to Chemia Biosciences, Inc. to develop computational technologies for discovering novel fungal natural products with potential antimicrobial and therapeutic applications. The primary goal is to create software that can predict the molecular structures of natural products encoded in fungal genomes, leveraging high-throughput...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $781,502 to Chemia Biosciences, Inc., a Pittsburgh-based small disadvantaged business, to develop NATDISCOVERY - efficient and accurate computational methods for identifying novel non-ribosomal peptides from complex mass spectral datasets. The overarching goal is to create a novel platform for discovering natural product...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports the development of efficient and accurate methods for identifying novel natural product small molecules from complex mass spectral datasets. The $275,484 award, which began on Sep 1, 2023 and runs through Aug 31, 2024, will enable the grantee, Chemia Biosciences, Inc., to integrate genome mining with computational metabolomics to...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under CFDA 93.310 (Trans-NIH Research Support) provides $1,148,000.00 to The Trustees of Princeton University to develop novel approaches for combating bacterial infections and antibiotic resistance. The key products/services to be delivered include: Utilizing single-cell RNA sequencing methods (M3-SEQ and Dual-M3-SEQ) to monitor host-pathogen interactions and phage dynamics at the single-cell level,...
This $298,045 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences (CFDA 93.350) aims to establish and develop a high-throughput screening (HTS) assay to identify novel bacterial DNA gyrase poisoning inhibitors. The key products and services to be delivered under this one-year award include: Developing a unique HTS assay to rapidly discover bacterial DNA gyrase poisoning inhibitors from small molecule libraries. This assay will...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...
This Project Grant award of $350,000.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop an artificial intelligence-based platform for optimizing peptide-based drug candidates. The key products or services to be delivered include: Methods for encoding non-canonical amino acids and cyclic peptides to enable high-performance machine learning on commercial peptide sequence, activity, stability, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover and develop new, more potent antifungal therapies for treating invasive fungal infections such as cryptococcosis, candidiasis, and aspergillosis. The funding will support the continued screening of chemical libraries to identify lead compounds that selectively inhibit the fungal ceramide synthase 1...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program provides $170,000.00 to Prokaryotics Incorporated, a pharmaceutical research company, to perform structure-based design of novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, MCD4. The research aims to develop mechanistically novel antifungal agents to address...